论文部分内容阅读
据《化学与工程新闻》周刊报道,80年代生物技术产品市场曾一度看好,但从90年代初开始,生物技术产品开发的成功率急剧下降,其中生物技术药物开发过程尤为艰辛。许多生物技术公司在94年仍无力扭转财政困境。许多有市场前景的产品目前仍在待批或处于开发状态,有些产品甚至在临床试验中就已失败。而Agouron, Biogen, Cephalon,Chiron,Genetech等公司也遭受了试验失败或产品停产的挫折。 产品的回落使小公司遭受的损失更大。生物技术产业的股票价格在94年的大部分时间都一直处于下降状态。据《化学工程新闻》周刊对一些生物技术公司的股票行情的调查,在1994年上半年生物医药股票的价格指数下降了15％以上。
According to the “Chemicals and Engineering News” weekly report, the biotechnology product market was once promising in the 1980s, but since the early 1990s, the success rate of biotechnological product development has been drastically reduced, and the development process of biotechnology drugs is particularly difficult. Many biotech companies are still unable to reverse their financial difficulties in 1994. Many products with market prospects are still pending approval or development, and some products have even failed in clinical trials. Companies such as Agouron, Biogen, Cephalon, Chiron, and Genetech also suffered setbacks due to trial failure or product discontinuation. The fall in the product made the smaller company suffer even more. The stock price of the biotechnology industry has been declining for most of the 94 years. According to a survey conducted by the “Chemical Engineering News” weekly on the stock prices of some biotechnology companies, the price index of biomedical stocks fell by more than 15% in the first half of 1994.